An integrated surrogate model for screening of drugs against mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1380-1391

  Gupta, Antima ^a   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Drug susceptibility testing; Mycobacterium aurum; RAW 264.7 macrophages; SPOTi assay; Surrogate

Indexed keywords

AMINOSALICYLIC ACID; CEPHALOSPORIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; FOSFOMYCIN; ISONIAZID; METRONIDAZOLE; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG TOLERANCE; HIGH THROUGHPUT SCREENING; MACROPHAGE; MOUSE; MYCOBACTERIUM AURUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH; RELIABILITY; SPOT CULTURE GROWTH INHIBITION ASSAY;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84861134859     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks056     Document Type: Article

References (47)

1. WHO Report. Global Tuberculosis Control. Geneva, Switzerland: WHO Press, 2011.
2. Guzman JD, Gupta A, Bucar F et al. Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds. Front Biosci 2012; 17: 1861-81.
3. Guzman JD, Wube A, Evangelopoulos D et al. Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. J Antimicrob Chemother 2011; 66: 1766-72.
4. Guzman JD, Gupta A, Evangelopoulos D et al. Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 2101-7.
5. Sun D, Scherman MS, Jones V et al. Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity. Bioorg Med Chem 2009; 17: 3588-94.
6. Khare G, Kar R, Tyagi AK. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs. PLoS One 2011; 6: e22441.
7. Gupta A, Kaul A, Tsolaki AG et al. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 2011; 217: 363-74.
8. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 2001; 81 Suppl 1: 1-52.
9. Chaturvedi V, Dwivedi N, Tripathi RP et al. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis. J Gen Appl Microbiol 2007; 53: 333-7.
10. Gordien AY, Gray AI, Franzblau SG et al. Antimycobacterial terpenoids from Juniperus communis L. (Cuppressaceae). J Ethnopharmacol 2009; 126: 500-5.
11. O'Donnell G, Gibbons S. Antibacterial activity of two canthin-6-one alkaloids from Allium neapolitanum. Phytother Res 2007; 21: 653-7.
12. Carvalho R, de Sonneville J, Stockhammer OW et al. A high throughput screen for tuberculosis progression. PLoS One 2011; 6: e16779.
13. Khan A, Sarkar D. A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J Microbiol Methods 2008; 73: 62-8.
14. Belisle JT, Vissa VD, Sievert T et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276: 1420-2.
15. Lacave C, Laneelle MA, Daffe M et al. Mycolic acid metabolic filiation and location in Mycobacterium aurum and Mycobacterium phlei. Eur J Biochem 1989; 181: 459-66.
16. Gupta N, Singh BN. Deciphering kas operon locus in Mycobacterium aurum and genesis of a recombinant strain for rational-based drug screening. J Appl Microbiol 2008; 105: 1703-10.
17. Gupta A, Bhakta S, Kundu S et al. Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high throughput antituberculosis drug screening. J Antimicrob Chemother 2009; 64: 774-81.
18. Altaf M, Miller CH, Bellows DS et al. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb) 2010; 90: 333-7.
19. Wiese M, Seydel U. Drug effects on intracellular mycobacteria determined by mass spectrometric analysis of the Na(+)-to-K+ ratios of individual bacterial organisms. Antimicrob Agents Chemother 1996; 40: 2047-53.
20. Bhakta S, Besra GS, Upton AM et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. J ExpMed 2004; 199: 1191-9.
21. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. Methods Mol Biol 2010; 642: 193-201.
22. Council Directive 90/679/EEC of 26 November 1990 on the protection of workers from risks related to exposure to biological agents at work. Official J Europ commun 1990; L 374.
23. 2+ levels. Infect Immun 2000; 68: 4518-22.
24. Portaels F, Pattyn SR. Growth of mycobacteria in relation to the pH of the medium. Ann Microbiol (Inst Pasteur) 1982; 133: 213-21.
25. Hu Y, Coates AR, Mitchison DA. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006; 10: 317-22.
26. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
27. Lim A, Eleuterio M, Hutter B et al. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J Bacteriol 1999; 181: 2252-6.
28. Watanabe S, Zimmermann M, Goodwin MB et al. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog 2011; 7: e1002287.
29. Sala C, Dhar N, Hartkoorn RC et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 4150-8.
30. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
31. Turner DJ, Hoyle SL, Snewin VA et al. An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis. Microbiology 2002; 148: 2929-36.
32. Heifets L, Higgins M, Simon B. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 2000; 4: 491-5.
33. Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb) 2004; 84: 110-30.
34. Brown KA, Ratledge C. The effect of p-aminosalicyclic acid on iron transport and assimilation in mycobacteria. Biochim Biophys Acta 1975; 385: 207-20.
35. Patole J, Shingnapurkar D, Padhye S et al. Schiff base conjugates of p-aminosalicylic acid as antimycobacterial agents. Bioorg Med Chem Lett 2006; 16: 1514-7.
36. Fattorini L, Tan D, Iona E et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother 2003; 47: 360-2.
37. Toennies G, Gallant DL. Bacterimetric studies; factors affecting the precision of bacterial growth responses and their measurement. J Biol Chem 1948; 174: 451-63.
38. Arbex MA, Varella Mde C, de Siqueira HR et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 2010; 36: 626-40.
39. Ramon-Garci{dotless}́a S, Ng C, Anderson H et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high throughput screen. Antimicrob Agents Chemother 2011; 55: 3861-9.
40. Yamane N, Nakasone I, Yamashita K et al.[Determination of pyrazinamide susceptibility for Mycobacterium tuberculosis by use of Middlebrook culture media and comparison with results of pyrazinamidase test.] Rinsho Byori 1998; 46: 479-85.
41. De Logu A, Onnis V, Saddi B et al. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 2002; 49: 275-82.
42. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
43. Arbex MA, Varella Mde C, de Siqueira HR et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second-line drugs. J Bras Pneumol 2010; 36: 641-56.
44. David S. Synergic activity of D-cycloserine and b-chloro-D-alanine against Mycobacterium tuberculosis. J Antimicrob Chemother 2001; 47: 203-6.
45. Marshall G, Blacklock JWS, Cameron C et al. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-82.
46. Herbert D, Paramasivan CN, Venkatesan P et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmicand stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-9.
47. Heifets LB, Iseman MD, Cook JL et al. Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. Antimicrob Agents Chemother 1985; 27: 11-5.